We operate from a purpose-built 65,000ft² (6,000m²) GMP facility in Bristol, designed to support cell and gene therapy developers from early-stage clinical programmes through to commercial manufacture. Our facility includes fully qualified Grade C cleanrooms, integrated fill-finish capability, QC labs, GMP warehousing, and 12,000ft² of expansion space for additional clinical, pivotal, or commercial manufacturing capacity.
Apr 11, 2025
What is our scale of operation?
We operate from a purpose-built 65,000ft² (6,000m²) GMP facility in Bristol, designed to support cell and gene therapy developers from early-stage clinical programmes through to commercial manufacture. Our facility includes fully qualified Grade C cleanrooms, integrated fill-finish capability, QC labs, GMP warehousing, and 12,000ft² of expansion space for additional clinical, pivotal, or commercial manufacturing capacity.
Latest News
Why AAV Gene Therapy Innovation Must Align with Manufacturing Readiness
Apr 13, 2026
Blog
FDA’s CGT Flexibilities: Clarity for Developers, Complexity for Strategy
Mar 20, 2026
Blog
eXmoor Pharma appoints Manuel Balbuena as Chief Commercial Officer to strengthen global commercial strategy
Mar 3, 2026
Industry News
Let’s Accelerate Your Therapy Together
Whether you're in early-stage development or scaling up for commercial production, eXmoor Pharma provides the expertise and flexibility you need. Partner with us to move your therapy forward with confidence.